Scienceforbrain is a Lithuanian deep-tech medical device company founded in 2023 to prevent brain damage and improve neurological outcomes in patients undergoing complex clinical cardiac procedures.
In 2025, following the European Innovation Council (EIC) Accelerator interview stage, for which the company received targeted preparation support from the EEN2EIC project representatives, Scienceforbrain was awarded the EIC Seal of Excellence. Shortly thereafter, the company secured EUR 2.5 million in funding from the Lithuanian Transfer Fund, enabling further development and commercialization of its breakthrough technology.
Scienceforbrain company is developing BrainProtect technology, the first non-invasive, AI-powered plug-in system designed to monitor and actively manage cerebral blood flow autoregulation in real time during cardiopulmonary bypass (CPB) surgery, ECMO treatment, and intensive care. Unlike conventional monitoring tools that can monitor systemic parameters (BP, oxygenation, brain perfusion flow velocity), BrainProtect integrates with heart-lung machines to generate controlled blood flow modulation, detect early signs of impaired cerebral autoregulation within seconds, and enable clinicians to immediately optimize individual patient-specific cerebral perfusion. Built on decades of neurocritical care research, supported by a strong international patent portfolio and clinical validation, Scienceforbrain aims to establish cerebral autoregulation monitoring as a new standard of care in cardiac surgery and critical care medicine to reduce the frequencies of post operative cognitive disfunction and delirium.
Speaking about the early stages of his career, the company’s co-founder, Professor Dr Arminas Ragauskas, recalled that his work in this field began as early as 1993–1995. Over the decades, he and his team accumulated extensive scientific and clinical expertise, steadily advancing their research and technological capabilities.
This long-term commitment to innovation ultimately led to the decision to establish Scienceforbrain and bring their breakthrough technology closer to patients. Recognising the scale of their ambition — particularly the need to conduct multicentre clinical trials across Europe — pursuing funding through the European Innovation Council (EIC) became a strategic choice. “We set ourselves a two year goal to win the EIC Accelerator programme competition and we succeeded. We secured the grant for several reasons. First and foremost, our work is grounded in truly fundamental science with strong breakthrough potential. Our innovation is inherently value adding and has the capacity to transform the field in which we operate.”
The innovation developed by Scienceforbrain is grounded in the results of two prospective clinical studies conducted in Lithuania at Vilnius University Santaros Clinics and Lithuanian Life Sciences University Kaunas Clinics. These studies provided strong clinical validation and laid the foundation for the further advancement of the company’s technology.
Building on this scientific evidence, Scienceforbrain has established international collaborations with partners ranging from Finland to the United States. To protect its intellectual property and support global expansion, the company holds patents in both the European Union and the United States. Its work is further reinforced by a strong portfolio of high-impact scientific publications, demonstrating the robustness and credibility of the underlying research.
When speaking about the core team behind BrainProtect, Dr Arminas Ragauskas emphasised that the company is built on long-standing professional relationships and shared experience.
According to him, the entire team consists either of scientists or trusted professionals from their close circle who bring strong business expertise. Rather than being assembled intentionally at a single point in time, the team evolved organically over the years. These are individuals who grew together professionally, with the founder himself developing alongside them. He describes the team as a group of distinct and strong personalities united by a shared vision. Their collaboration extends beyond business objectives, it is grounded in mutual trust, long-term commitment, and a journey they continue not only as colleagues, but as people growing together through life.
When discussing the near-term plans to ensure the project’s success, the founder emphasised that effective risk management remains a top priority. The team brings substantial experience, having successfully implemented numerous multicentre projects across Europe and the United States, which provides a strong foundation for navigating the complexities ahead.
From a technological perspective, the company has already developed a patented and clinically validated solution. Continuous daily work with volunteers allows the team to compare results, refine the technology, and carefully determine the most strategic direction for further development.
At the same time, as the company operates at the forefront of cutting-edge medical technology, it is actively engaging in discussions with some of the largest companies in the field. These industry leaders understand the value of the solution and have expressed strong interest in potential collaboration.
From a regulatory standpoint, obtaining the necessary approvals is a critical next step. The devices are currently not yet approved by the FDA or CE marked in the European Union, both of which are essential for working with patients. Therefore, a key focus in the near future is securing all required regulatory clearances to enable clinical deployment and market entry.
Reflecting on the support received during the EIC Accelerator interview preparation, the Dr Arminas Ragauskas expressed strong appreciation for the Lithuanian Innovation Centre experts and the EEN2EIC project team. He described the assistance as sincere, highly professional, and truly valuable. In his view, there was no difference compared to working with similar organisations in the United States, where administrative representatives are just as motivated as the project teams themselves to achieve success and to ensure that public funding is used purposefully and effectively to create the greatest possible social and economical impact.
As the founder of Scienceforbrain, he emphasised that the EEN2EIC project brings together highly qualified professionals who provide precise guidance and respond quickly to emerging needs. Reflecting on the support received, he noted that Lithuania is often called a “magic country with magic people”, and said this is exactly how he would describe the experts behind EEN2EIC, whose dedication and genuine commitment to the company’s success truly make them “magic people.”
Scienceforbrain web page: https://scienceforbrain.com/
